Oncolytics Biotech, Inc (NASDAQ: ONCY)’s stock price has soared by 5.00% in relation to previous closing price of $0.75. Nevertheless, the company has seen a gain of 14.63% in its stock price over the last five trading days. prnewswire.com reported 2025-06-30 that SAN DIEGO and CALGARY, Alberta, June 30, 2025 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer. Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson.
Is It Worth Investing in Oncolytics Biotech, Inc (NASDAQ: ONCY) Right Now?
ONCY has 36-month beta value of 1.07. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ONCY is 85.98M, and currently, short sellers hold a 3.03% ratio of that float. The average trading volume of ONCY on July 03, 2025 was 792.30K shares.
ONCY’s Market Performance
ONCY stock saw an increase of 14.63% in the past week, with a monthly gain of 128.92% and a quarterly increase of 49.43%. The volatility ratio for the week is 9.40%, and the volatility levels for the last 30 days are 14.00% for Oncolytics Biotech, Inc (ONCY). The simple moving average for the past 20 days is 29.31% for ONCY’s stock, with a 1.03% simple moving average for the past 200 days.
Analysts’ Opinion of ONCY
Many brokerage firms have already submitted their reports for ONCY stocks, with Maxim Group repeating the rating for ONCY by listing it as a “Buy.” The predicted price for ONCY in the upcoming period, according to Maxim Group is $3 based on the research report published on October 06, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ONCY reach a price target of $15. The rating they have provided for ONCY stocks is “Buy” according to the report published on February 17th, 2021.
ONCY Trading at 46.96% from the 50-Day Moving Average
After a stumble in the market that brought ONCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.53% of loss for the given period.
Stock Fundamentals for ONCY
The total capital return value is set at -1.78. Equity return is now at value -211.24, with -115.29 for asset returns.
Based on Oncolytics Biotech, Inc (ONCY), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -19.18.
Currently, EBITDA for the company is -34.88 million with net debt to EBITDA at 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.21.
Conclusion
To put it simply, Oncolytics Biotech, Inc (ONCY) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
